Bill and Melinda Gates Foundation donations made to Drugs for Neglected Diseases initiative

This is an online portal with information on donations that were announced publicly (or have been shared with permission) that were of interest to Vipul Naik. The git repository with the code for this portal, as well as all the underlying data, is available on GitHub. All payment amounts are in current United States dollars (USD). The repository of donations is being seeded with an initial collation by Issa Rice as well as continued contributions from him (see his commits and the contract work page listing all financially compensated contributions to the site) but all responsibility for errors and inaccuracies belongs to Vipul Naik. Current data is preliminary and has not been completely vetted and normalized; if sharing a link to this site or any page on this site, please include the caveat that the data is preliminary (if you want to share without including caveats, please check with Vipul Naik). We expect to have completed the first round of development by the end of December 2019. See the about page for more details. Also of interest: pageview data on analytics.vipulnaik.com, tutorial in README, request for feedback to EA Forum.

Table of contents

Basic donor information

ItemValue
Country United States
Wikipedia pagehttps://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation
Best overview URLhttps://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation
Facebook username gatesfoundation
LinkedIn username bill-&-melinda-gates-foundation
Websitehttps://www.gatesfoundation.org/
Donations URLhttps://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database
Twitter usernamegatesfoundation
Page on philosophy informing donationshttps://www.gatesfoundation.org/What-We-Do
Grant application process pagehttps://www.gatesfoundation.org/How-We-Work/General-Information/Grantseeker-FAQ
Regularity with which donor updates donations datacontinuous updates
Regularity with which Donations List Website updates donations data (after donor update)irregular
Lag with which donor updates donations datamonths
Lag with which Donations List Website updates donations data (after donor update)years
Data entry method on Donations List WebsiteSQL insertion commands generated by script https://github.com/riceissa/gates-foundation-iati-processing

Brief history: The Gates Foundation launched in 2000, with precursors starting in the 1990s, financed by the personal wealth of co-founder Bill Gates from Microsoft. Starting 2005, it scaled up its giving significantly after a large funding commitment from Warren Buffett

Brief notes on broad donor philosophy and major focus areas: See https://www.gatesfoundation.org/Who-We-Are/General-Information/Foundation-Factsheet for the grantmaking areas. The four grantmaking areas are the Global Development Program, Global Health Program, Global Policy and Advocacy, and United States Program. Within the United States Program the focus is on K-12 education, the Internet, and emergency relief

Notes on grant publication logistics: Although the Gates Foundation has a grants database on its website, as well as individual grant pages for every grant, we use the IATI data instead, because it can be processed programmatically (the data on the site does not allow for full data download or easy programmatic processing). This leads to a few problems: first, IATI data does not include grants made in the United States, since it focuses on development assistance (DA) spending. Second, IATI data is updated more infrequently. Third, it may sometimes omit some information that is present in the grants database

Full donor page for donor Bill and Melinda Gates Foundation

Basic donee information

ItemValue
Country
Facebook page dndi.org
Websitehttps://www.dndi.org/
Twitter usernameDNDi
Wikipedia pagehttps://en.wikipedia.org/wiki/Drugs_for_Neglected_Diseases_Initiative
Instagram usernamedrugsforneglecteddiseases

Full donee page for donee Drugs for Neglected Diseases initiative

Donation amounts by cause area and year

If you hover over a cell for a given cause area and year, you will get a tooltip with the number of donees and the number of donations.

Note: Cause area classification used here may not match that used by donor for all cases.

Cause area Number of donations Total 2017 2015 2014 2013 2011 2010 2009 2007
Global health (filter this donor) 15 128,580,432.00 4,802,610.00 -1,335,450.00 63,743,680.00 2,352,649.00 16,787,659.00 1,500,000.00 15,000,000.00 25,729,284.00
Total 15 128,580,432.00 4,802,610.00 -1,335,450.00 63,743,680.00 2,352,649.00 16,787,659.00 1,500,000.00 15,000,000.00 25,729,284.00

Graph of spending by cause area and year (incremental, not cumulative)

Graph of spending should have loaded here

Graph of spending by cause area and year (cumulative)

Graph of spending should have loaded here

Full list of donations in reverse chronological order (15 donations)

Amount (current USD)Donation dateCause areaURLInfluencerNotes
4,802,610.002017-11-21Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop much needed new treatments for filarial diseases (onchocerciasis and lymphatic filariasis), human African trypanosomiasis and visceral leishmaniasis that are safe, effective, easy-to-use (oral) and affordable..; Aid type: Project-type interventions. Affected regions: Africa.
540,152.002016-05-09Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop much needed new treatments for filarial diseases (onchocerciasis and lymphatic filariasis), human African trypanosomiasis and visceral leishmaniasis that are safe, effective, easy-to-use (oral) and affordable..; Aid type: Project-type interventions. Affected regions: Africa.
-540,152.002016-05-09Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support the development of flubendazole as a macrofilaricidal drug candidate for treatment of onchocerciasis loa loa co-infections; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
-1,335,450.002015-11-11Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to establish and implement new treatment modalities as successful tools to control and support the elimination of Visceral Leishmaniasis in the most endemic regions of South Asia; Aid type: Project-type interventions. Affected regions: South & Central Asia.
59,867,584.002014-10-24Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop much needed new treatments for filarial diseases (onchocerciasis and lymphatic filariasis), human African trypanosomiasis and visceral leishmaniasis that are safe, effective, easy-to-use (oral) and affordable..; Aid type: Project-type interventions. Affected regions: Africa.
4,398,239.002014-07-10Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- for clinical development of Oral Fexinidazole for stage 2 Human African Trypanosomiasis; Aid type: Project-type interventions. Affected regions: South of Sahara.
1,000,000.002014-05-06Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- To foster exploration and innovation needed to identify, develop and deliver the right global health products to those most in need.; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
-1,522,143.002014-04-29Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support the development of flubendazole as a macrofilaricidal drug candidate for treatment of onchocerciasis loa loa co-infections; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
2,352,649.002013-06-26Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to identify new drug candidates for helminths and kinetoplastid diseases. NTD Screening. Investment start date: 11/2/2011 to end date: 3/31/2015. Grantee name: Drugs for Neglected Diseases initiative; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
2,000,000.002011-11-02Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to identify new drug candidates for helminths and kinetoplastid diseases. NTD Screening. Investment start date: 11/2/2011 to end date: 3/31/2015. Grantee name: Drugs for Neglected Diseases initiative; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
9,000,000.002011-06-23Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to establish and implement new treatment modalities as successful tools to control and support the elimination of Visceral Leishmaniasis in the most endemic regions of South Asia; Aid type: Project-type interventions. Affected regions: South & Central Asia.
5,787,659.002011-04-15Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to support the development of flubendazole as a macrofilaricidal drug candidate for treatment of onchocerciasis loa loa co-infections; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
1,500,000.002010-06-25Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop new drug candidates for human African trypanosomiasis and visceral leishmaniasis through the pre-clinical stage and ready for an Investigational New Drug filing, and the completion of phase I clinical studies; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.
15,000,000.002009-11-10Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- for clinical development of Oral Fexinidazole for stage 2 Human African Trypanosomiasis; Aid type: Project-type interventions. Affected regions: South of Sahara.
25,729,284.002007-11-12Global health/infectious disease controlhttps://iatiregistry.org/publisher/bmgf-- to develop new drug candidates for human African trypanosomiasis and visceral leishmaniasis through the pre-clinical stage and ready for an Investigational New Drug filing, and the completion of phase I clinical studies; Aid type: Project-type interventions. Affected regions: Developing countries, unspecified.